Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Syndax Pharmaceuticals (SNDX) Capital Expenditures (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has disclosed Capital Expenditures for 5 consecutive years, with $56000.0 as the latest value for Q4 2025.

For Q4 2025, Capital Expenditures changed N/A year-over-year to $56000.0; the TTM value through Dec 2025 reached $70000.0, up 400.0%, while the annual FY2025 figure was $187000.0, N/A changed from the prior year.
Capital Expenditures hit $56000.0 in Q4 2025 for Syndax Pharmaceuticals, up from $14000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $56000.0 in Q4 2025 and bottomed at $56000.0 in Q4 2025.